The news: Eli Lilly is hiking the UK price of its diabetes and weight loss drug Mounjaro by as much as 170% starting next month, depending on the dose size. The drugmaker also said it’s been working on aligning prices of its medications across developed countries.

How we got here: Lilly is responding to President Donald Trump’s demand that pharma companies equalize how much the US and other wealthy countries pay for prescription drugs.

Lilly said in a statement that to meet Trump’s goal of lowering US drug prices, the amount governments and health systems pay for medications must increase in markets like Europe. For context: Brand-name drugs on average are priced more than four times higher in the US than in similar nations, per RAND research. Lilly’s blockbuster GLP-1s carry a list price of over $1,000 per month in the US. In the UK, it’s far lower—about £122, or $165.

A key caveat: The UK price of Mounjaro will nearly triple in some cases, but not everyone will bear the brunt of the additional costs. Patients who access Mounjaro through the National Health Service (NHS) in England will be absolved from the higher price, a Lilly spokesperson told Reuters.

Many people in the UK who take GLP-1s for weight loss, as opposed to type 2 diabetes, get them through private healthcare providers. The new price surge could affect those providers and their patients.

Our take: Pharma manufacturers could benefit from the incredible complexity of drug pricing, because it will be hard to know whether they’re truly equalizing prices or just finding ways around the Trump administration’s demands that other drugmakers could copy. For instance, Lilly will soon be able to tell Trump that it has constructed a rebalancing so that the US is no longer getting ripped off on what it pays for prescription drugs. However, a pharma company raising list prices in international markets doesn’t mean US consumers will suddenly pay less.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.